Randomized, Placebo-Controlled Trial of Clodronate in Patients With Primary Operable Breast Cancer

Abstract

Clodronate, given to patients with primary operable breast cancer, may reduce the occurrence of bone metastases, although this reduction was only significant during this medication period. There was a significant reduction in mortality.